Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforceKathryn Connelly, Cristina Vazquez‐Mateo, Vera Golder et al.|Nature Reviews Rheumatology|2023Cited by 29
LP-179 Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosusCristina Arriens, Coburn Hobar, Anca Askanase et al.|Unknown|2023Cited by 0